Caribou Biosciences to Present CAR-T Clinical Trial Data at ASH 2026

PUBT · 22h ago
Caribou Biosciences to Present CAR-T Clinical Trial Data at ASH 2026
  • Caribou Biosciences will present clinical findings for vispa-cel and CB-011 at the American Society of Hematology meeting, December 12-15, 2026.
  • The abstracts preceded plans to explore strategic alternatives and discontinue both programs because of the financing environment for allogeneic CAR-T therapies.
  • The December 14 ANTLER presentation will describe multiyear complete remissions with vispa-cel in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
  • The December 12 CaMMouflage presentation will describe deep, durable responses to CB-011 in heavily pretreated patients with relapsed or refractory multiple myeloma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caribou Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040900PRIMZONEFULLFEED9869552) on November 04, 2026, and is solely responsible for the information contained therein.